Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14
Status:
Completed
Trial end date:
2019-05-13
Target enrollment:
Participant gender:
Summary
To validate the ability of the Methacetin Breath Test (MBT) to detect clinically significant
portal hypertension (CSPH)/severe portal hypertension (SPH) defined as hepatic venous
pressure gradient (HVPG) ≥ 10 mmHg and HVPG ≥ 12 mmHg respectively, in patients with
non-alcoholic steatohepatitis (NASH) during the course of treatment with Conatus's
investigational product emricasan/placebo.